Is Thermo Fisher Scientific (TMO) Pricing Look Reasonable After Recent Share Price Weakness

Simply Wall St.02-05

If you are wondering whether Thermo Fisher Scientific's current share price reflects its long term potential, you are not alone. This article will help you frame what the recent moves might mean for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609390041?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/97023-main-header/1756189961534","is_english":true,"pubTime":"2026-02-05 02:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609390041","market":"nz","top_or_hot":-1,"title":"Is Thermo Fisher Scientific (TMO) Pricing Look Reasonable After Recent Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Thermo Fisher Scientific's current share price reflects its long term potential, you are not alone. This article will help you frame what the recent moves might mean for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/is-thermo-fisher-scientific-tmo-pricing-look-reasonable-afte\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Thermo Fisher Scientific (TMO) Pricing Look Reasonable After Recent Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Thermo Fisher Scientific (TMO) Pricing Look Reasonable After Recent Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-05 02:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/is-thermo-fisher-scientific-tmo-pricing-look-reasonable-afte><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Thermo Fisher Scientific's current share price reflects its long term potential, you are not alone. This article will help you frame what the recent moves might mean for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/is-thermo-fisher-scientific-tmo-pricing-look-reasonable-afte\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1023059063.AUD","symbol_name":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/is-thermo-fisher-scientific-tmo-pricing-look-reasonable-afte","article_id":"2609390041","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/97023-main-header/1756189961534"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/is-thermo-fisher-scientific-tmo-pricing-look-reasonable-afte","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2609390041","pubTimestamp":1770229627,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Thermo Fisher Scientific's current share price reflects its long term potential, you are not alone. This article will help you frame what the recent moves might mean for value focused investors.\nThe stock last closed at US$570.09, with returns of an 8.6% decline over the past 7 days, a 3.8% decline over the past month, and a 3.8% decline year to date, while the 1 year return is a 1.5% decline and the 5 year return stands at 18.1%.\nRecent share price moves have...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","IE00B19Z8W00.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"A\" INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4566":"资本集团","IE00B19Z8X17.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH  \"AG\" (USD) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2720916845.USD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU2125910179.SGD":"Natixis Thematics Water H-R/A SGD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU2764263039.SGD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (SGDHDG) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU2211814178.USD":"ALLIANZ CLEAN PLANET \"AT\" (USD) ACC","LU2764263203.CNY":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (CNYHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2125910336.SGD":"Natixis Thematics Water R/A SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","TMO":"赛默飞世尔","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1923621640.USD":"Natixis Thematics Water R/A USD","LU2360108059.USD":"BGF CIRCULAR ECONOMY \"A4\" (USD) INC","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0061474960.USD":"天利环球焦点基金AU Acc","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0557290698.USD":"施罗德环球可持续增长基金","LU2764262908.HKD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4121":"生命科学工具和服务","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","LU0096362180.USD":"CT (LUX) I GLOBAL FOCUS \"DU\" (USD)","LU1803068623.USD":"TEMPLETON GLOBAL CLIMATE CHANGE \"AH1\" (USDHDG) ACC"},"translate_title":"近期股价疲软后，赛默飞世尔科技(TMO)的定价看起来合理吗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"TMO":1.5},"content_text":"If you are wondering whether Thermo Fisher Scientific's current share price reflects its long term potential, you are not alone. This article will help you frame what the recent moves might mean for value focused investors. The stock last closed at US$570.09, with returns of an 8.6% decline over the past 7 days, a 3.8% decline over the past month, and a 3.8% decline year to date, while the 1 year return is a 1.5% decline and the 5 year return stands at 18.1%. Recent share price moves have come as investors continue to assess Thermo Fisher Scientific's position in pharmaceuticals and biotech tools and services, including its role as a key supplier across research and clinical markets. These shifts in sentiment provide useful context when you think about whether the current price lines up with the underlying business. On our valuation checks Thermo Fisher Scientific scores 2 out of 6 for being undervalued. Next we will look at how traditional methods like P/E and discounted cash flow stack up, and then finish with a way to think about valuation that can give you an even clearer view of the stock.  Thermo Fisher Scientific scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Thermo Fisher Scientific Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a business could be worth by projecting its future cash flows and then discounting those back to today’s value. For Thermo Fisher Scientific, the model used here is a 2 Stage Free Cash Flow to Equity approach. The company’s last twelve month free cash flow is about $6.3b. Analysts provide explicit forecasts for the next few years, with Simply Wall St extending those into longer term projections. Under these assumptions, projected free cash flow reaches about $9.8b in 2028, with further years extrapolated through 2035 using more moderate growth estimates. When all those future cash flows are discounted back using this model, the estimated intrinsic value comes out at about $521.79 per share. Compared with the recent share price of roughly $570.09, the DCF output suggests the stock is around 9.3% overvalued. This is a relatively small gap and within the sorts of swings often seen in the market. Result: ABOUT RIGHT Thermo Fisher Scientific is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act. TMO Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Thermo Fisher Scientific. Approach 2: Thermo Fisher Scientific Price vs Earnings For a profitable business like Thermo Fisher Scientific, the P/E ratio is a useful shorthand for how much investors are currently paying for each dollar of earnings. It brings earnings, which are a core driver of long term value, into direct comparison with the share price. What counts as a “normal” P/E depends on what investors expect for future growth and how much risk they see in those earnings. Higher growth or lower perceived risk can support a higher P/E, while lower growth or higher risk usually points to a lower, more cautious multiple. Thermo Fisher Scientific currently trades on a P/E of 31.95x. That sits below the Life Sciences industry average of 36.99x and close to the peer group average of 32.95x. Simply Wall St’s proprietary Fair Ratio for Thermo Fisher Scientific is 31.18x, which reflects factors such as its earnings growth profile, industry, profit margins, market cap and key risks. This Fair Ratio can be more tailored than a simple peer or industry comparison because it aims to account for the company’s own characteristics rather than assuming all firms deserve the same multiple. With the actual P/E only modestly above the Fair Ratio, the shares look slightly expensive on this metric. Result: OVERVALUED NYSE:TMO P/E Ratio as at Feb 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1422 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Thermo Fisher Scientific Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way to put your own story about Thermo Fisher Scientific behind the numbers such as fair value, future revenue, earnings and margins. A Narrative links what you believe about the company, for example its role across research and clinical markets, to a financial forecast and then to a fair value that you can compare with today’s share price to help decide whether you might buy, hold or sell. On Simply Wall St, millions of investors use Narratives on the Community page as an easy tool that updates automatically when new information like news or earnings is added, so your view does not stay frozen. For Thermo Fisher Scientific, one investor might build a Narrative that assumes a higher fair value based on strong demand for tools and services, while another might choose a lower fair value if they focus more on risks or a more cautious outlook. Do you think there's more to the story for Thermo Fisher Scientific? Head over to our Community to see what others are saying! NYSE:TMO 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Thermo Fisher Scientific might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609390041","isCrawlerRequest":true}